MNMD

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023. Last year, the FDA approved 55 treatment protocols that included previously unapproved ingredients or compounds, a significant increase from the 37 approvals in 2022 and surpassing the annual average of 45-to-50 approvals. This uptick suggests that biotech stocks are regaining momentum and are poised to push new products to market.

Despite this positive trend, high interest rates and other market uncertainties persist. If you’re considering investing in biotech breakthrough stocks this year, focus on those with strong prospects and sufficient cash reserves to sustain operations over the long term.

Mind Medicine (MNMD)

MNMD stock: A scientist holding a test tube in a stock image. AI Recommended Biotech Stocks

Source: Shutterstock

Like many biotech breakthrough stocks, psychedelics companies reached their zenith during the pandemic-era zero-interest-rate policy (ZIRP) exuberance in 2021. However, despite a significant drop from those highs, small-cap psychedelic therapy company Mind Medicine (NASDAQ:MNMD) is quietly positioning itself as a major contender in the broader pharmaceutical landscape.

Recently, Mind Medicine achieved a significant milestone by securing a breakthrough therapy designation from the FDA for its LSD-based anxiety disorder treatment protocol. Initial tests showed that a single dosage of this treatment improved patient outcomes by 65% after 12 weeks. This performance contrasts with Johnson & Johnson’s (NYSE:JNJ) ketamine-based anxiety treatment, which requires multiple doses from the start and appears to have a broader range of negative side effects.

Although Mind Medicine has not yet reached profitability, it is preparing to advance its LSD anxiety treatment to Phase III trials later this year. With multiple other treatments in its pipeline, Mind Medicine is one of the most compelling biotech breakthrough stocks for those looking to diversify away from traditional pharmaceuticals.

Arcellx (ACLX)

A variety of pills, pill bottles, and droppers arranged on a table in multiple bright colors.

Source: Shutterstock

Arcellx (NASDAQ:ACLX) is a unique player among biotech breakthrough stocks focusing on cancer and autoimmune diseases by virtue of a monumental partnership with Gilead Sciences (NASDAQ:GILD) to develop pioneering CAR-T therapeutics. Unlike traditional cancer treatments, which often involve surgery, chemotherapy, and radiation — methods with severe side effects and inconsistent results — CAR-T therapies radically shift the paradigm by utilizing the patient’s own immune system. This method “trains” immune cells to recognize and kill cancer cells, offering clear advantages over conventional approaches.

The innovation associated with CAR-T therapies, however, comes at a high cost. Fortunately for Arcellx, Gilead is taking on much of the financial load. Gilead supports Arcellx with an $85 million cash payment and a $200 million stock purchase plan, providing Arcellx with sufficient funds to operate through 2027 as they continue their mission to revolutionize cancer treatment.

Beam Therapeutics (BEAM)

GENE Stock. a stylized image of a Doctor touching a medical clamp a DNA molecule

Source: Natali_ Mis/ShutterStock.com

Beam Therapeutics (NASDAQ:BEAM) stands out among our biotech breakthrough stocks as a high-stakes prospect. As a gene therapy and editing enterprise, Beam could become a massive multibagger if its technologies succeed, akin to what has been seen with Crispr Therapeutics (NASDAQ:CRSP) and its advances in gene editing for sickle cell treatments. However, Beam’s own sickle cell therapeutic is still in the testing phase, with promising early indications. Results from initial tests involving the editing and insertion of cells into bone marrow transplants are expected in the latter half of 2024.

Looking beyond sickle cell disease, Beam expects 2024 to generate massive developments, according to CEO John Evans. The company’s ambitious plans sit atop a solid financial cushion, boasting a robust cash reserve of approximately $1.2 billion. This financial cushion is critical, as it ensures Beam can sustain its operations and research through 2027 without the financial pressures that beleaguer many other firms in the biotech sector. This strong financial footing will support a variety of therapeutic developments in the coming years, especially as gene-editing tech evolves.

On the date of publication, Jeremy Flint held no positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Jeremy Flint, an MBA graduate and skilled finance writer, excels in content strategy for wealth managers and investment funds. Passionate about simplifying complex market concepts, he focuses on fixed-income investing, alternative investments, economic analysis, and the oil, gas, and utilities sectors. Jeremy’s work can also be found at www.jeremyflint.work.

More From InvestorPlace

The post Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine appeared first on InvestorPlace.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.